<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73923">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01969643</url>
  </required_header>
  <id_info>
    <org_study_id>SGNLVA-001</org_study_id>
    <nct_id>NCT01969643</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-LIV1A in Breast Cancer Patients</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to examine the safety and tolerability of SGN-LIV1A in
      patients with metastatic breast cancer, and to find the highest dose of the drug that can be
      given without unacceptable side effects.  Other goals of the trial are to find out if
      SGN-LIV1A has any antitumor effects, to learn about the pharmacokinetics of SGN-LIV1A, and
      to explore the relationship between antigen expression and SGN-LIV1A effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-LIV1A and metabolites</measure>
    <time_frame>Through 3 weeks after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival relative to prior therapy</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SGN-LIV1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-LIV1A every 3 weeks by intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-LIV1A</intervention_name>
    <description>by intravenous infusion every 3 weeks</description>
    <arm_group_label>SGN-LIV1A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of breast cancer with radiographic evidence of
             metastatic disease

          -  One of the following: a) Triple-negative disease (ER/PR/HER2-negative) and received
             at least 2 prior cytotoxic regimens in the metastatic setting; or b) ER- and/or
             PR-positive/HER2-negative disease and received at least 2 prior cytotoxic regimens in
             the metastatic setting and are no longer a candidate for hormonal therapy

          -  Positive for LIV-1 expression by central pathology review on newly obtained tumor
             tissue biopsy

          -  Measurable disease

          -  Eastern Cooperative Oncology Group performance status 0 or 1

        Exclusion Criteria:

          -  Pre-existing neuropathy Grade 2 or higher

          -  Malignant CNS disease that has not been definitively treated

          -  P-gp inducers/inhibitors or strong CYP3A inducers/inhibitors within 2 weeks before
             first dose
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Kostic, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terri Lowe</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Martin</last_name>
      <phone>205-975-3198</phone>
      <email>djmartin@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center / Samuel Oschin Comprehensive Cnacer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Naessig</last_name>
      <phone>310-423-0721</phone>
      <email>virginia.naessig@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Grist</last_name>
      <phone>317-278-6680</phone>
      <email>acgrist@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Kathy Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University Department of Oncology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarice Zuccaro</last_name>
      <phone>313-576-9375</phone>
      <email>zuccaroc@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Patricia LoRusso, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Roos</last_name>
      <phone>507-538-7036</phone>
      <email>roos.michelle@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Minetta Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Pedigo</last_name>
      <phone>615-329-7432</phone>
      <email>heather.pedigo@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Howard Burris III</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Mesher</last_name>
      <phone>206-288-2056</phone>
      <email>mollerup@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Specht, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Monomethyl auristatin E</keyword>
  <keyword>Antibody-drug conjugate</keyword>
  <keyword>Drug therapy</keyword>
  <keyword>Metastatic</keyword>
  <keyword>LIV-1 protein, human</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
